For: | Jiang ZN, Ahmed SMU, Wang QC, Shi HF, Tang XW. Quinone oxidoreductase 1 is overexpressed in gastric cancer and associated with outcome of adjuvant chemotherapy and survival. World J Gastroenterol 2021; 27(22): 3085-3096 [PMID: 34168410 DOI: 10.3748/wjg.v27.i22.3085] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v27/i22/3085.htm |
Number | Citing Articles |
1 |
Fereshte Ghorbani, Afrooz Mazidimoradi, Arezou Biyabani, Leila Allahqoli, Hamid Salehiniya. Role of NADPH Quinone Reductase 1 (NQO1) Polymorphism in Prevention, Diagnosis, and Treatment of Gastrointestinal Cancers. Current Cancer Drug Targets 2024; 24(12): 1213 doi: 10.2174/0115680096283149240109094710
|
2 |
Lei Cao, Yuanqin Chen, Shuangta Xu, Hongwei Cheng. Is NAD(P)H quinone oxidoreductase 1 a tumor promoter or suppressor in gastric cancer?. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1143108
|
3 |
Ran Xu, Ying Liu, Liang Ma, Yao Sun, Haifeng Liu, Yang Yang, Tiefeng Jin, Dawei Yang. NQO1/CPT1A promotes the progression of pancreatic adenocarcinoma via fatty acid oxidation. Acta Biochimica et Biophysica Sinica 2023; 55(5): 758 doi: 10.3724/abbs.2023066
|
4 |
Giovanni Tossetta, Daniela Marzioni. Targeting the NRF2/KEAP1 pathway in cervical and endometrial cancers. European Journal of Pharmacology 2023; 941: 175503 doi: 10.1016/j.ejphar.2023.175503
|